08/12/2022
•2024Viewpoint
Video Highlights from Visby Medical’s Breakfast Panel at 2022 IDSOG Annual Meeting
Watch video highlights from “The Neglected Epidemic: A Panel Discussion about the Value Rapid POC PCR brings to Reproductive Health” panel discussion at the 2022 IDSOG Annual Meeting.
Visby Medical hosted a breakfast panel at The IDSOG Annual Meeting titled “The Neglected Epidemic: A Panel Discussion about the Value Rapid POC PCR brings to Reproductive Health” featuring Tosin Jaiyeoba Goje, MD, MSCR, FACOG and Christina Muzny, MD, MSPH, FACP, FIDSA.
Below are video highlights from the panel discussion.
Why do black women bear a higher burden of disease?
Tosin Jaiyeoba Goje, MD, MSCR, FACOG
Cleveland Clinica Lerner College of Medicine
Case Western Reserve University
Case Presentation: “Tina”
Tosin Jaiyeoba Goje, MD, MSCR, FACOG
Cleveland Clinica Lerner College of Medicine
Case Western Reserve University
Christina Muzny, MD, MSPH, FACP, FIDSA
University of Alabama at Birmingham
Final Assessment of Case Presentation: “Tina”
Tosin Jaiyeoba Goje, MD, MSCR, FACOG
Cleveland Clinica Lerner College of Medicine
Case Western Reserve University
Christina Muzny, MD, MSPH, FACP, FIDSA
University of Alabama at Birmingham
Learn more about the Visby Medical Sexual Health Test
Read more articles & insights
CARB-X awards funding to Visby Medical for gonorrhea, antibiotic susceptibility test
The Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) announced today that it will award biotechnology company Visby Medical of San Jose, California, up to $1.8 million
Visby Medical™ Receives FDA Clearance and CLIA Waiver for second Generation Sexual Health Test for Women
Visby Medical™ announced today that it has received 510(k) clearance and was granted a CLIA waiver from the FDA for its 2nd generation point of
Visby Medical Receives FDA Emergency Use Authorization for Respiratory Health Test for Use in CLIA Waived Settings
Visby Medical announced today that it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration for its Respiratory Health point of
Visby Medical Expands Series E Round to Over $135 Million
Visby Medical announced today that it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration for its Respiratory Health point of
